{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:03:23Z","timestamp":1771880603182,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,1]]},"DOI":"10.1097\/qai.0b013e3181d9a354","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T10:58:40Z","timestamp":1271329120000},"page":"82-86","source":"Crossref","is-referenced-by-count":9,"title":["Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers"],"prefix":"10.1097","volume":"55","author":[{"given":"Matthijs","family":"van Luin","sequence":"first","affiliation":[]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[]},{"given":"Eleonora W J","family":"van Ewijk-Beneken Kolmer","sequence":"additional","affiliation":[]},{"given":"Corrien P W G M","family":"Verweij-van Wissen","sequence":"additional","affiliation":[]},{"given":"Bas","family":"Schouwenberg","sequence":"additional","affiliation":[]},{"given":"Arjen","family":"Hoitsma","sequence":"additional","affiliation":[]},{"given":"Hugo G","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"David M","family":"Burger","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers.","volume":"47","author":"Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/108729103321655854","article-title":"Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir\/ritonavir in a patient with HIV.","volume":"17","author":"Mah Ming","year":"2003","journal-title":"AIDS Patient Care STDS"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1086\/344179","article-title":"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.","volume":"35","author":"Hare","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01.aids.0000216373.53819.92","article-title":"Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.","volume":"20","author":"Aberg","year":"2006","journal-title":"AIDS"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study.","volume":"357","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.","volume":"37","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0090-9556(25)08889-0","article-title":"Biotransformation of pravastatin sodium in humans.","volume":"19","author":"Everett","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/QAD.0b013e328303be40","article-title":"Severe rhabdomyolysis associated with raltegravir use.","volume":"22","author":"Zembower","year":"2008","journal-title":"AIDS"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0091270009345689","article-title":"The effect of raltegravir on the glucuronidation of lamotrigine.","volume":"49","author":"Van Luin","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1128\/AAC.00005-08","article-title":"Lack of a significant drug interaction between raltegravir and tenofovir.","volume":"52","author":"Wenning","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/588794","article-title":"Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.","volume":"47","author":"Iwamoto","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.clpt.6100281","article-title":"Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.","volume":"83","author":"Iwamoto","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201009010-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:03:33Z","timestamp":1740013413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201009010-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181d9a354","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}